Tag: ravulizumab

AstraZeneca’s Danicopan yields promising results in ALPHA Phase 3 trial in PNH

businessnewstoday- December 12, 2023

In a significant development in the healthcare industry, AstraZeneca has released positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA ... Read More

AstraZeneca to acquire US biopharma company Alexion Pharmaceuticals for $39bn

pharmanewsdaily- December 14, 2020

AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in ... Read More

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

pharmanewsdaily- January 15, 2020

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral ... Read More

Alexion bags Ultomiris EU approval for paroxysmal nocturnal hemoglobinuria

pharmanewsdaily- July 5, 2019

Ultomiris EU approval : Alexion Pharmaceuticals has secured approval from the European Commission (EC) for its C5 complement inhibitor Ultomiris (ravulizumab) for the treatment of ... Read More